The EDCTP Alumni Network

Call	Career Development Fellowship (CDF)
Programme	EDCTP2
Start Date	2019-09-01
End Date	2023-08-31
Project Code	TMA2018CDF-2345 PrazOpt
Status	Active

Title

Optimization of praziquantel therapy for Schistosoma mansoni infection in preschool-aged children in Ethiopia: PrazOpt

Objectives

Primary Objective: The primary objective of this study is to determine curative rate of praziquantel 40 mg/kg single dose in S. mansoni infection in preschool-aged children. Secondary objectives of this clinical research are to: - Determine egg reduction rate - Assess safety outcomes (adverse events) - Estimate pharmacokinetic parameters - Assess polymorphisms of gene for praziquantel metabolizing enzymes - Identify correlates of curative outcome.

Host Organisation

Institution	Country
Addis Ababa University	Ethiopia

Participants

Name	Institution	Country
Prof Eyasu Makonnen	CDT-Africa	Ethiopia
Prof Eleni Aklillu	Karolinska Institute	Sweden
Dr Birkineh Tilahun	Hawassa University	Ethiopia

Study Design

This study is a prospective observational study which assesses treatment outcome of S. mansoni infected preschool-aged children who got praziquantel treatment. So, the study doesn’t have any interventions except collection of biological specimen for safety and efficacy evaluations.

Sites

The study sites include health centers in districts of Sidama, where there is a high burden of schistosomiasis infection. These include Bushulo Health Center (Loke district), Wosha Health Center (Wosha district) and Chuko Health Center (Chuko district).

Students Supervised

Type	Name	Title	University	Start Date	End Date
MSc	Mahlet Abbay	Prevalence and treatment outcome of schistosomiasis in preschool-aged children: A systematic review and meta-analysis	Addis Ababa University	2019	2020
PhD	Tafese Tadele	Burden of schistosomiasis in preschool-aged children and the determinants of treatment outcome	Hawassa University	2019	2022

Call	EDCTP Clinical Research & Development Fellowship (R&D F)
Programme	EDCTP2
Start Date	2016-05-01
End Date	2018-05-01
Project Code	TMA2014-434
Status	Completed

Title

Novartis Institute for Biomedical Research (NIBR), Switzerland

Host Organisation

Institution	Country
Addis Ababa University (AAU)	Ethiopia

Current Organisation

Addis Ababa University

Current Job Title

Associate Professor

Students Supervised

Type	Name	Title	University	Start Date	End Date
MSc	Lemma Bose	Evaluation of liver toxicity associated with protease inhibitors based anti-retro viral treatment	Addis Ababa University	2017	2018
MSc	Yitayal Ababu	Cardiometabolic syndrome associated with protease inhibitors based anti-retro viral treatment	Addis Ababa University	2017	2018
MSc	Markos Tadele	Identification of anti-leishmanial lead compounds from open access pathogen box	Addis Ababa University	2016	2018
PhD	Tafese Tadele	Schistosomiasis burden and its health outcomes in preschool Children in Hawassa	Hawassa University	2020	2023
MSc	Mahlet Abbay	Prevalence and treatment outcome of schistosomiasis in preschool children: meta-analysis	Addis Ababa University	2019	2020
MSc	Gabriel Dawit	Azithromycin versus amoxicillin-clavulanate for otitis media in children	Addis Ababa University	2019	2020
MSc	Frehiwot Ginbaru	Treatment outcome of dolutegravir based regimen versus efavirenz based first line regimen in HIV patients at Zewditu Memorial Hospital: Comparative Study	Addis Ababa University	2019	2020

Memberships

Role	Committee/board	Start Date	End Date
Member and Secretary	Institutional Review Board	2017
Member and Secretary	Exit Examination Board	2015	2017
Member	Panel of experts for the College of Health Sciences CPD [Continuing Professional Development] accreditation	2019
Member	National Drug Safety Advisory	2020

Education

Institution	Degree	Year
University of Camerino, Italy	PhD	2014-07-15
Addis Ababa University, Ethiopia	MSc	2005-02-01
,

Areas Of Specialisation

Human Immuno-deficiency Virus (HIV) Malaria Neglected Infectious Diseases (NID)

Grants

Grant Code:

TMA2018CDF-2345 PrazOpt

Source of funding:

European and Developing Countries Clinical Trials Partnership (EDCTP)

Amount:

150000

Role:

Principal Investigator

Start Date:

2019-01-01

End Date:

2022-01-01

Grant Code:

Challenge grant

Source of funding:

MMV

Amount:

50000

Role:

Principal Investigator

Start Date:

2016-08-31

End Date:

2018-12-31

Grant Code:

Source of funding:

Addis Ababa University

Amount:

30000

Role:

Principal Investigator

Start Date:

2021-01-01

End Date:

2024-01-01

Publications

Authors:

Abay SM , author
Deribe K , author
Reda AA , author
Biadgilign S , author
Datiko D , author
Assefa T , author
Todd M , author
Deribew A , author

Date:

2015-08-01

Journal:

Journal of the International Association of Providers of AIDS Care

Content:

Identifiers:

PMID: 26289343
DOI: 10.1177/2325957415599210

Authors:

Sinisi A , author
Millán E , author
Abay SM , author
Habluetzel A , author
Appendino G , author
Muñoz E , author
Taglialatela-Scafati O , author

Date:

2015-06-01

Journal:

Journal of natural products

Content:

Identifiers:

PMID: 26115003
DOI: 10.1021/acs.jnatprod.5b00179

Authors:

Debela Abdeta , author
Solomon Mequanente Abay , author
Mirutse Giday , author
Nigatu Kebede , author
Getechew Terefe , author
Bernard Marchand , editor

Date:

2021-12-29

Journal:

Journal of Parasitology Research

Content:

Identifiers:

DOI: 10.1155/2021/1239379

Authors:

Abay SM , author

Date:

2013-09-01

Journal:

Parasites & vectors

Content:

Identifiers:

PMID: 24499628
PMC: PMC3849011
DOI: 10.1186/1756-3305-6-278

Authors:

GBD 2016 Healthcare Access and Quality Collaborators , author

Date:

2018-06-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 29893224
PMC: PMC5986687
DOI: 10.1016/S0140-6736(18)30994-2

Authors:

GBD 2016 Alcohol Collaborators , author

Date:

2018-08-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30146330
PMC: PMC6148333
DOI: 10.1016/S0140-6736(18)31310-2

Authors:

GBD 2017 SDG Collaborators , author

Date:

2018-11-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30496107
PMC: PMC6227911
DOI: 10.1016/S0140-6736(18)32281-5

Authors:

Abay SM , author
Tilahun M , author
Fikrie N , author
Habtewold A , author

Date:

2013-06-01

Journal:

Journal of infection in developing countries

Content:

Identifiers:

PMID: 23771290
DOI: 10.3855/jidc.2658

Authors:

Tadele M, Abay SM, Makonnen E, Hailu A

Date:

2020-03-31

Journal:

Drug Design, Development and Therapy

Content:

Introduction: Leishmaniasis is a collective term used to describe various pathological conditions caused by an obligate intracellular protozoan of the genus Leishmania. It is one of the neglected diseases and has been given minimal attention by drug discovery and development stakeholders to narrow the safety and efficacy gaps of the drugs currently used to treat leishmaniasis. The challenge is further exacerbated by the emergence of drug resistance by the parasites.

Methods: Aiming to look for potential anti-leishmanial hits and leads, we screened Medicines for Malaria Venture (MMV) Pathogen Box compounds against clinically isolated Leishmania donovani strain. In this medium-throughput primary screening assay, the compounds were screened against promastigotes, and then against amastigote stages.

Results: From the total 400 compounds screened, 35 compounds showed >50% inhibitory activity on promastigotes in the initial screen (1 μM). Out of these compounds, nine showed >70% inhibition, with median inhibitory concentration (IC₅₀) ranging from 12 to 491 nM using the anti-promastigote assay, and from 53 to 704 nM using the intracellular amastigote assay. Identified compounds demonstrated acceptable safety profiles on THP-1 cell lines and sheep red blood cells, and had appropriate physicochemical properties suitable for further drug development. Two compounds (MMV690102 and MMV688262) were identified as leads. The anti-tubercular agent MMV688262 (delamanid) showed a synergistic effect with amphotericin B, indicating the prospect of using this compound for combination therapy.

Conclusion: The current study indicates the presence of additional hits which may hold promise as starting points for anti-leishmanial drug discovery and in-depth structure-activity relationship studies.

Identifiers:

Authors:

Markos Tadele , author
Solomon M. Abay , author
Eyasu Makonnen , author
Asrat Hailu , author

Date:

2019-07-26

Journal:

Content:

Identifiers:

DOI: 10.1101/716134

Authors:

D'Alessandro S, Corbett Y, Ilboudo DP, Misiano P, Dahiya N, Abay SM, Habluetzel A, Grande R, Gismondo MR, Dechering KJ, Koolen KM, Sauerwein RW, Taramelli D, Basilico N, Parapini S.

Date:

2015-06-08

Journal:

Antimicrob Agents Chemother. 2015 Sep;59(9):5135-44. doi: 10.1128/AAC.04332-14.

Content:

Identifiers:

Authors:

Dahiya N , author
Chianese G , author
Abay SM , author
Taglialatela-Scafati O , author
Esposito F , author
Lupidi G , author
Bramucci M , author
Quassinti L , author
Christophides G , author
Habluetzel A , author
Lucantoni L , author

Date:

2016-10-01

Journal:

Phytomedicine : international journal of phytotherapy and phytopharmacology

Content:

Identifiers:

PMID: 27912876
DOI: 10.1016/j.phymed.2016.10.019

Authors:

Ebstie YA , author
Abay SM , author
Tadesse WT , author
Ejigu DA , author

Date:

2016-07-01

Journal:

Drug design, development and therapy

Content:

Identifiers:

PMID: 27528800
PMC: PMC4970641
DOI: 10.2147/DDDT.S61443

Authors:

Markos Tadele , author
Solomon M Abay , author
Eyasu Makonnen , author
Asrat Hailu , author

Date:

2020-03-01

Journal:

Drug Design, Development and Therapy

Content:

Identifiers:

DOI: 10.2147/DDDT.S244903

Authors:

Abay SM , author
Lucantoni L , author
Dahiya N , author
Dori G , author
Dembo EG , author
Esposito F , author
Lupidi G , author
Ogboi S , author
Ouédraogo RK , author
Sinisi A , author
Taglialatela-Scafati O , author
Yerbanga RS , author
Habluetzel A , author

Date:

2015-07-01

Journal:

Malaria journal

Content:

Identifiers:

PMID: 26208861
PMC: PMC4513948
DOI: 10.1186/s12936-015-0812-2

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors:

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators , author

Date:

2018-11-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30496104
PMC: PMC6227754
DOI: 10.1016/S0140-6736(18)32279-7

Authors:

Dawit A. Ejigu , author
Solomon M. Abay , author

Date:

2020-04-30

Journal:

Tuberculosis Research and Treatment

Content:

Identifiers:

DOI: 10.1155/2020/5907839

Authors:

Makida Kemal , author
Gemechu Tadesse , author
Adem Esmael , author
Solomon Mequanente Abay , author
Tadesse Kebede , author

Date:

2019-12-01

Journal:

BMC Research Notes

Content:

Identifiers:

DOI: 10.1186/s13104-019-4246-8

Authors:

Dembo EG , author
Abay SM , author
Dahiya N , author
Ogboi JS , author
Christophides GK , author
Lupidi G , author
Chianese G , author
Lucantoni L , author
Habluetzel A , author

Date:

2015-02-01

Journal:

Parasites & vectors

Content:

Identifiers:

PMID: 25884799
PMC: PMC4330930
DOI: 10.1186/s13071-015-0700-1

Authors:

Million Loha , author
Abay Mulu , author
Solomon M. Abay , author
Wondwossen Ergete , author
Bekesho Geleta , author

Date:

2019-03-10

Journal:

Evidence-Based Complementary and Alternative Medicine

Content:

Identifiers:

DOI: 10.1155/2019/5702159

Authors:

Ejigu DA and Abay SM

Date:

2020-04-30

Journal:

Tuberculosis Research and Treatment

Content:

Oxidative stress is a common feature of tuberculosis (TB), and persons with reduced antioxidants are at more risk of TB. TB patients with relatively severe oxidative stress had also more advanced disease as measured by the Karnofsky performance index. Since adverse effects from anti-TB drugs are also mediated by free radicals, TB patients are prone to side effects, such as hearing loss. In previous articles, researchers appealed for clinical trials aiming at evaluating N-acetyl cysteine (NAC) in attenuating the dreaded hearing loss during multidrug-resistant TB (MDR-TB) treatment. However, before embarking on such trials, considerations of NAC's overall impact on TB treatment are crucial. Unfortunately, such a comprehensive report on NAC is missing in the literature and this manuscript reviews the broader effect of NAC on TB treatment. This paper discusses NAC's effect on mycobacterial clearance, hearing loss, drug-induced liver injury, and its interaction with anti-TB drugs. Based on the evidence accrued to date, NAC appears to have various beneficial effects on TB treatment. However, despite the favorable interaction between NAC and first-line anti-TB drugs, the interaction between the antioxidant and some of the second-line anti-TB drugs needs further investigations.

Identifiers:

Authors:

Abay SM

Date:

2013-09-24

Journal:

Parasit Vectors. 2013 Sep 24;6(1):278. doi: 10.1186/1756-3305-6-278.

Content:

Identifiers:

Authors:

Befekadu Wolde , author
Solomon Mequanente Abay , author
Dereje Nigussie , author
Belete Legesse , author
Eyasu Makonnen , author
Teklie Mengie Ayele , author

Date:

2022-04-01

Journal:

Infection and Drug Resistance

Content:

Identifiers:

DOI: 10.2147/IDR.S360761

Authors:

Dembo E , author
Ogboi J , author
Abay S , author
Lupidi G , author
Dahiya N , author
Habluetzel A , author
Lucantoni L , author

Date:

2014-07-01

Journal:

Journal of medical entomology

Content:

Identifiers:

PMID: 25118416
DOI: 10.1603/me13112

Authors:

Abay SM , author
Amelo W , author

Date:

2010-07-01

Journal:

Journal of young pharmacists : JYP

Content:

Identifiers:

PMID: 21042491
PMC: PMC2964771
DOI: 10.4103/0975-1483.66798

Authors:

GBD 2017 Causes of Death Collaborators , author

Date:

2018-11-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30496103
PMC: PMC6227606
DOI: 10.1016/S0140-6736(18)32203-7

Authors:

Makida Kemal
Gemechu Tadesse
Adem Esmael
Solomon Mequanente Abay
Tadesse Kebede

Date:

2019-04-05

Journal:

BMC Research Notes

Content:

Objective: Preschool age children (PSAC) are excluded from community based praziquantel treatment programs mainly due to paucity of evidence on the magnitude of schistosomiasis, efficacy and safety of this treatment in PSAC. The aim of this study is to assess Schistosoma mansoni infection rate and evaluate response to praziquantel in PSAC. A facility based longitudinal study was employed from April to June 2016 at Erer Health Center, Eastern Ethiopia. Stool sample was examined for schistosomiasis in 236 PSAC and repeated after 4 weeks post-treatment in positive individuals. Treatment outcomes were recorded and interpreted.

Results: Out of the 236 study participants, 59 (25%) were infected with S. mansoni. Praziquantel treatment (40 mg/kg) resulted in 96.4% cure rate and 99.4% egg reduction rate. Children of 3-5 year old were significantly affected with S. mansoni infection. Nausea and fatigue were common mild adverse events within 4 h of treatment however moderate and severe adverse events and allergic reactions were not observed. In conclusion, praziquantel at 40 mg/kg, the dose utilized in standard care for school age children, is tolerable and efficacious in the treatment of S. mansoni infection in PSAC, which calls for the healthcare system to provide appropriate service for this population.

Identifiers:

Authors:

GBD 2017 Mortality Collaborators , author

Date:

2018-11-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30496102
PMC: PMC6227504
DOI: 10.1016/S0140-6736(18)31891-9

Authors:

Abay SM, Tilahun M, Fikrie N, Habtewold A.

Date:

2013-06-25

Journal:

J Infect Dev Ctries. 2013 Jun 15;7(6):468-74. doi: 10.3855/jidc.2658.

Content:

Identifiers:

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors:

GBD 2017 DALYs and HALE Collaborators , author

Date:

2018-11-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30415748
PMC: PMC6252083
DOI: 10.1016/S0140-6736(18)32335-3

Authors:

Abay SM, Deribe K, Reda AA, Biadgilign S, Datiko D, Assefa T, Todd M, Deribew A.

Date:

2015-08-19

Journal:

J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14(6):560-70. doi: 10.1177/2325957415599210.

Content:

Identifiers:

Authors:

Debela Abdeta , author
Nigatu Kebede , author
Mirutse Giday , author
Getachew Terefe , author
Solomon Mequanente Abay , author

Date:

2020-09-22

Journal:

Evidence-Based Complementary and Alternative Medicine

Content:

Identifiers:

DOI: 10.1155/2020/8146756

Authors:

D'Alessandro S , author
Corbett Y , author
Ilboudo DP , author
Misiano P , author
Dahiya N , author
Abay SM , author
Habluetzel A , author
Grande R , author
Gismondo MR , author
Dechering KJ , author
Koolen KM , author
Sauerwein RW , author
Parapini S , author

Date:

2015-06-01

Journal:

Antimicrobial agents and chemotherapy

Content:

Identifiers:

PMID: 26055362
PMC: PMC4538477
DOI: 10.1128/AAC.04332-14

Authors:

Ebstie YA, Abay SM, Tadesse WT, Ejigu DA.

Date:

2016-07-26

Journal:

Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443.

Content:

Identifiers:

Authors:

Mulugeta Molla , author
Negero Gemeda , author
Solomon M. Abay , author

Date:

2017-01-01

Journal:

Evidence-Based Complementary and Alternative Medicine

Content:

Identifiers:

DOI: 10.1155/2017/4103410

Authors:

Teklie Mengie , author
Solomon Mequanente , author
Dereje Nigussie , author
Belete Legesse , author
Eyasu Makonnen , author

Date:

2021-05-01

Journal:

Journal of Inflammation Research

Content:

Identifiers:

DOI: 10.2147/JIR.S298244

Authors:

GBD 2017 Population and Fertility Collaborators , author

Date:

2018-11-01

Journal:

Lancet (London, England)

Content:

Identifiers:

PMID: 30496106
PMC: PMC6227915
DOI: 10.1016/S0140-6736(18)32278-5

Authors:

Yismaw G , author
Abay S , author
Asrat D , author
Yifru S , author
Kassu A , author

Date:

2010-10-01

Journal:

Ethiopian medical journal

Content:

Identifiers:

PMID: 21280431

Authors:

Haile Tazeze , author
Solomon Mequanente , author
Dereje Nigussie , author
Belete Legesse , author
Eyasu Makonnen , author
Teklie Mengie , author

Date:

2021-10-01

Journal:

Journal of Inflammation Research

Content:

Identifiers:

DOI: 10.2147/JIR.S339289

Authors:

Debela Abdeta , author
Nigatu Kebede , author
Mirutse Giday , author
Getachew Terefe , author
Solomon Mequanente Abay , author

Date:

2019-09-05

Journal:

Content:

Identifiers:

DOI: 10.21203/rs.2.13929/v1

Projects

Fellow:

Solomon Abay

Collaborators:

Name	Country	Institution
Prof Eyasu Makonnen	Ethiopia	Addis Ababa University
Prof Eleni Aklillu	Sweden	Karolinska Institute
Dr Birkineh Tilahun	Ethiopia	Hawassa University

Objectives:

Sites:

- The study sites include health centers in districts of Sidama Zone, Southern Nations Nationalities and Peoples Region (SNNPR), where there is a high burden of schistosomiasis infection. These include Bushulo Health Center (Loke district), Wosha Health Center (Wosha district) and Chuko Health Center (Chuko district).

Study Design:

Observational prospective study

Subjects:

Preschool aged children infected with S. mansoni

Linked Grant:

Optimization of praziquantel therapy for Schistosoma mansoni infection in preschool-aged children in Ethiopia: PrazOpt

Start Date:

2019-09-01

End Date:

2022-08-31

EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

Dr Solomon Abay

Title

Objectives

Host Organisation

Participants

Study Design

Sites

Students Supervised

Title

Host Organisation

Current Organisation

Current Job Title

Students Supervised

Memberships

Education

Areas Of Specialisation

Grants

Publications

Projects

Send a Message